News

Latest News

Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU<sup>®</sup> (Elacestrant) in Metastatic Breast Cancer at ASCO 2023

Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023

FLORENCE (Italy) and New York, NY, May 26, 2023 – The Menarini Group (“Menarini”), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics...
Botticelli, the inquietude and the beauty

Botticelli, the inquietude and the beauty

Successful artist, sensitive interpreter of the culture of his time and author of extraordinarily relevant works, Sandro Botticelli was a master of beauty.  With his...
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting

Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting

FLORENCE (Italy) and New York, NY, May 9, 2023 – The Menarini Group (“Menarini”), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics...
Birth rate emergency, younger generations say: “It’s not just an issue of economic stability”

Birth rate emergency, younger generations say: “It’s not just an issue of economic stability”

This was the overall sentiment that emerged during the second event held by the Menarini International Foundation’s Think Tank ON RADAR, which brought together 45 participants...
The doors of Europe open wide for the Volpi Rosse Menarini

The doors of Europe open wide for the Volpi Rosse Menarini

The Menarini Volpi Rosse team has now crossed the border and is on their way to Europe. The Florentine team will be the first wheelchair basketball team to represent Tuscany on an...
Menarini announces an exclusive distribution agreement for Boditech’s AFIAS-10 system

Menarini announces an exclusive distribution agreement for Boditech’s AFIAS-10 system

FLORENCE, ITALY, April 21 2023, A.Menarini Diagnostics S.r.l. (Menarini) is pleased to announce an exclusive distribution agreement for the AFIAS-10 System and IGRA-TB Assay (among...
The Dates of the XXVII Edition of the International Fair Play Menarini Awards

The Dates of the XXVII Edition of the International Fair Play Menarini Awards

FLORENCE, April 13, 2023 – Preparations are already underway for the International Fair Play Menarini Awards.  This year,  the event that pays tribute to athletes who...
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO<sup>®</sup> (selinexor)

Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor)

NEWTON, Mass. and FLORENCE, Italy, – February 21st, 2023 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer...
Menarini Group are with the Turkish and Syrian populations

Menarini Group are with the Turkish and Syrian populations

The hearts and thoughts of the Menarini Group are with the Turkish and Syrian populations affected by the recent and devastating earthquake. All our employees and their families can...
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations

FLORENCE (Italy) and New York City (U.S.) January 30th, 2023 – The Menarini Group (“Menarini”), a leading Italian pharmaceutical and diagnostics company, announced...
Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

(DUBLIN, Ireland and FLORENCE, Italy, December 19, 2022) - Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies,...
Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH<sup>®</sup> System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early

Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early

Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the...
Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS)

Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS)

FLORENCE, Italy, November 30th, 2022 - The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics...
Lost childhood: a 'tight-knit' network to combat abuse and distress

Lost childhood: a 'tight-knit' network to combat abuse and distress

Rome, December 7th, 2022 – Setting real changes in motion through dialogue among experts in order to tackle the unresolved issues of juvenile distress. This was the topic addressed...
Le Volpi Rosse Menarini continuano la loro avventura in Serie A

Le Volpi Rosse Menarini continuano la loro avventura in Serie A

Page available only in Italian language

QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform

QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform

NEWCASTLE UPON TYNE, UK and FLORENCE, ITALY, 2nd November 2022, QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point-of-Need molecular...
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

NEWTON, Mass. and FLORENCE, Italy,– November 1st, 2022 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer...
Nasce ON RADAR il laboratorio di pensieri, idee, dialogo

Nasce ON RADAR il laboratorio di pensieri, idee, dialogo

Page available only in Italian language

1345678910Last

News Archive

 

Company Profile

Download Pdf

youtube Youtube

linkedin Linkedin

Blog Item Image
MENARINI EMPLOYEES
make all the difference, every day.

We are looking for talented people: in order to achieve our mission we need energetic, versatile people with initiative and team-work skills.
Every day we do our jobs with a great sense of commitment, knowing that we are adding more value to the creation of quality drugs.

READ MORE




menarini pills of art

Menarini Pills of Art

Today, with ‘Pills of Art’, Menarini enters the city’s museums to reveal some of the curious facts on the works of the most well-known Renaissance painters. An initiative which confirms the company’s affiliation with art, a close connection which has led them to publish, each year and for more than six decades, an art monograph

Read More
Fair Play Menarini

International Fair Play Menarini Award

International Fair Play Menarini Award: the annual event which celebrates those sporting champions who have stood out in the world of sports for the brilliant results attained whilst fully respecting the rules

Read More
Menarini and Farmindustria

Menarini and Farmindustria: together we won’t rest

COVID -19 has brought many changes to our habits and our daily lives, but together we can face - and overcome - our fears. Menarini and Farmindustria, like all of us, won't rest.

Read More
EFPIA

EFPIA - We won’t rest campaign

MENARINI SUPPORTS THE EFPIA CAMPAIGN - WE WON'T REST: Disease never takes a break, so neither do we. We won't rest until people around the world see a brighter tomorrow.

Read More
newsletter

Subscribe to the newsletter

Subscribe to the newsletter to be updated on Menarini news.

Subscribe
Media Contact

Media Contact

To access the service it is necessary to declare to have read the privacy information.

Read More

The Menarini Blog

MENARINI BLOG

  • Menarini4People
The Volpi Rosse Menarini toast to an exciting season in Italy and Europe
Read More
  • Menarini4People
World Hypertension Day: Menarini is committed to fighting the “silent killer”.
Read More
  • Menarini4People
  • WeAreMenarini
A thousand trees for a healthier future: Menarini takes the lead on World Asthma Day
Read More

menarini for people

Discover our responsibility projects to stand close to people

read more